

CROWN BIOSCIENCE

MuPrime™ Tumor Homografts

Immunocompetent models carrying clinically-relevant oncogenic mutations

A JSR Life Sciences Company

QUICKFACT

V1.0

MuPrime models are homografts of spontaneous or carcinogen induced GEMM tumors grafted in immuno-competent syngeneic hosts. Developed from virtually any GEMM, tumor homografts are broadening the number and molecular pathology of syngeneic models for preclinical I/O research.

MuPrime tumor homografts are never passaged *in vitro* or *ex vivo*. As a result, the original tumor histopathology, molecular pathology, and key oncogenic driver mutations are preserved.

The **MuPrime** platform offers:

- Unique models, encompassing disease-specific mutations relevant to human cancers
- The predictive power of GEMM combined with operational simplicity required for *in vivo* pharmacology studies
- A fully competent mouse immune system
- Well-characterized models with histopathology, immune checkpoint and SoC benchmarking, and immune profiling data available via our online database **MuBase**
- Scalability that enables large-scale screening



Kras (G12D)/Trp53 null/Pdx1-cre (KPC) tumor homograft model for the evaluation of novel pancreatic ductal adenocarcinoma (PDAC) treatments





Patient PDAC



Mouse PDAC from KPC GEMM



Subcutaneous homograft tumor



Orthotopic homograft tumor

Get in touch

Sales
US: +1 858 622 2900
UK: +44 870 166 6234
busdev@crownbio.com
www.crownbio.com

Science
consultation@crownbio.com